Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00102778 · ClinicalTrials.gov registry record · Phase 2
GW873140 In Combination With Kaletra In HIV Infected Subjects
A Phase 2 study, sponsored by ViiV Healthcare.
- Terminated
- Registry status
- Phase 2
- Development phase
- 175
- Enrollment target
NCT00102778 is a Phase 2 study that was terminated before completion, run by ViiV Healthcare. The registered enrollment target is 175 participants.
The verdict
NCT00102778, a Phase 2 study, was terminated before completion, sponsored by ViiV Healthcare.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 175 participants
- Enrollment target
Study Summary
This study is a 96-week study designed to evaluate the safety and efficacy of GW873140 in combination with Kaletra in HIV infected, untreated subjects.
Interventions
- DRUG Kaletra (lopinavir/ritonavir)
- DRUG GW873140
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2004-12 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00102778
The ClinicalTrials.gov registry entry for NCT00102778 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Kaletra (lopinavir/ritonavir) is the first listed.
NCT00102778 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00102778 about?
NCT00102778 is a clinical study titled "GW873140 In Combination With Kaletra In HIV Infected Subjects". This study is a 96-week study designed to evaluate the safety and efficacy of GW873140 in combination with Kaletra in HIV infected, untreated subjects.
What is the current status of trial NCT00102778?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 175 participants. The study started on 2004-12. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00102778?
The interventions under investigation include: Kaletra (lopinavir/ritonavir) (DRUG), GW873140 (DRUG).
Who is sponsoring clinical trial NCT00102778?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.